We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The increasing opacity of gene therapy.
- Abstract
Suggests that gene therapy trials in which deaths occur should be more closely scrutinized. Competition for funds; Why researchers who observed deaths did not report them to the United States National Institutes of Health (NIH) or the US Food and Drug Administration (FDA); How many deaths and adverse side effects went unreported; How the Recombinant DNA Advisory Committee (RAC) has been weakened.
- Subjects
UNITED States; GENE therapy &; ethics; EXPERIMENTAL genetics; NATIONAL Institutes of Health (U.S.); UNITED States. Food &; Drug Administration; NATIONAL Institutes of Health (U.S.). Recombinant DNA Advisory Committee
- Publication
Nature, 1999, Vol 402, Issue 6758, p107
- ISSN
0028-0836
- Publication type
Article
- DOI
10.1038/45865